Yongchao Dou
Overview
Explore the profile of Yongchao Dou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
2617
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yi X, Zhao H, Hu S, Dong L, Dou Y, Li J, et al.
Cell Rep Methods
. 2024 Nov;
4(11):100906.
PMID: 39561714
We developed a Bayesian-based algorithm to infer gene expression states in individual samples and incorporated it into a workflow to identify tumor-associated antigens (TAAs) across 33 cancer types using RNA...
2.
Zhao T, Xu S, Ping J, Jia G, Dou Y, Henry J, et al.
Br J Cancer
. 2024 Oct;
131(11):1796-1804.
PMID: 39468330
Background: Genome-wide association studies (GWAS) have identified more than 200 breast cancer risk-associated genetic loci, yet the causal genes and biological mechanisms for most loci remain elusive. Proteins, as final...
3.
Savage S, Yi X, Lei J, Wen B, Zhao H, Liao Y, et al.
Cell
. 2024 Jun;
187(16):4389-4407.e15.
PMID: 38917788
Fewer than 200 proteins are targeted by cancer drugs approved by the Food and Drug Administration (FDA). We integrate Clinical Proteomic Tumor Analysis Consortium (CPTAC) proteogenomics data from 1,043 patients...
4.
Anurag M, Strandgaard T, Kim S, Dou Y, Comperat E, Al-Ahmadie H, et al.
iScience
. 2024 Mar;
27(3):109179.
PMID: 38439961
Urothelial carcinoma (CIS) is an aggressive phenotype of non-muscle-invasive bladder cancer. Molecular features unique to CIS compared to high-grade papillary tumors are underexplored. RNA sequencing of CIS, papillary tumors, and...
5.
Savage S, Wang Y, Chen L, Jewell S, Newton C, Dou Y, et al.
Clin Proteomics
. 2024 Jan;
21(1):7.
PMID: 38291365
Background: Omics characterization of pancreatic adenocarcinoma tissue is complicated by the highly heterogeneous and mixed populations of cells. We evaluate the feasibility and potential benefit of using a coring method...
6.
Yue F, Ku A, Stevens P, Michalski M, Jiang W, Tu J, et al.
bioRxiv
. 2024 Jan;
PMID: 38260423
ZNRF3 and RNF43 are closely related transmembrane E3 ubiquitin ligases with significant roles in development and cancer. Conventionally, their biological functions have been associated with regulating WNT signaling receptor ubiquitination...
7.
Dou Y, Katsnelson L, Zhang B, Fenyo D, Liu T
Clin Transl Med
. 2023 Nov;
13(11):e1477.
PMID: 38009415
No abstract available.
8.
Dou Y, Liu Y, Yi X, Olsen L, Zhu H, Gao Q, et al.
Nat Commun
. 2023 Sep;
14(1):5809.
PMID: 37726316
Shotgun proteomics is essential for protein identification and quantification in biomedical research, but protein isoform characterization is challenging due to the extensive number of peptides shared across proteins, hindering our...
9.
Liao Y, Savage S, Dou Y, Shi Z, Yi X, Jiang W, et al.
Cell Syst
. 2023 Aug;
14(9):777-787.e5.
PMID: 37619559
By combining mass-spectrometry-based proteomics and phosphoproteomics with genomics, epi-genomics, and transcriptomics, proteogenomics provides comprehensive molecular characterization of cancer. Using this approach, the Clinical Proteomic Tumor Analysis Consortium (CPTAC) has characterized...
10.
Li Y, Dou Y, Veiga Leprevost F, Geffen Y, Calinawan A, Aguet F, et al.
Cancer Cell
. 2023 Aug;
41(8):1397-1406.
PMID: 37582339
The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) investigates tumors from a proteogenomic perspective, creating rich multi-omics datasets connecting genomic aberrations to cancer phenotypes. To facilitate pan-cancer investigations,...